AstraZeneca’s (AZN) “Buy” Rating Reiterated at Berenberg Bank

Berenberg Bank reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Monday morning, MarketBeat reports. Berenberg Bank currently has a GBX 140 ($1.73) price target on the biopharmaceutical company’s stock.

A number of other research firms also recently commented on AZN. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a £140 ($173.05) price objective on shares of AstraZeneca in a report on Friday, November 22nd. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the stock. According to MarketBeat, AstraZeneca has an average rating of “Moderate Buy” and a consensus target price of GBX 7,935.67 ($98.09).

AstraZeneca Price Performance

Shares of AZN stock opened at £107.54 ($132.93) on Monday. The firm has a market cap of £166.69 billion, a price-to-earnings ratio of 3,413.97, a PEG ratio of 0.86 and a beta of 0.17. AstraZeneca has a 12 month low of GBX 9,461 ($116.95) and a 12 month high of £133.88 ($165.49). The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The stock has a 50-day moving average price of £104.96 and a 200 day moving average price of £116.70.

Insider Buying and Selling at AstraZeneca

In related news, insider Tony Mok acquired 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were acquired at an average cost of £126.80 ($156.74) per share, for a total transaction of £190,200 ($235,105.07). Also, insider Pascal Soriot bought 20,000 shares of AstraZeneca stock in a transaction that occurred on Thursday, November 14th. The stock was bought at an average cost of £102.03 ($126.12) per share, with a total value of £2,040,600 ($2,522,373.30). Insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.